The role of inflammation in ICU-acquired weakness
- PMID: 20727229
- PMCID: PMC2945106
- DOI: 10.1186/cc9187
The role of inflammation in ICU-acquired weakness
Abstract
A pilot observational study by Weber-Carstens and colleagues contributes to a mechanistic explanation of the puzzling and complex phenomena of ICU-acquired weakness (ICU-AW). The authors suggest systemic, inflammatory-mediated pathology is the most significant risk factor for ICU-AW. While this finding is somewhat equivocal, it provides important direction for future investigations and illustrates the challenges of interpreting significance in small observational studies.
Comment on
-
Risk factors in critical illness myopathy during the early course of critical illness: a prospective observational study.Crit Care. 2010;14(3):R119. doi: 10.1186/cc9074. Epub 2010 Jun 18. Crit Care. 2010. PMID: 20565863 Free PMC article.
Similar articles
-
Increased Early Systemic Inflammation in ICU-Acquired Weakness; A Prospective Observational Cohort Study.Crit Care Med. 2017 Jun;45(6):972-979. doi: 10.1097/CCM.0000000000002408. Crit Care Med. 2017. PMID: 28350642
-
Intensive care unit-acquired weakness: unanswered questions and targets for future research.F1000Res. 2019 Apr 17;8:F1000 Faculty Rev-508. doi: 10.12688/f1000research.17376.1. eCollection 2019. F1000Res. 2019. PMID: 31069055 Free PMC article. Review.
-
Autonomic dysfunction in ICU-acquired weakness: a prospective observational pilot study.Intensive Care Med. 2013 Sep;39(9):1610-7. doi: 10.1007/s00134-013-2991-z. Epub 2013 Jun 21. Intensive Care Med. 2013. PMID: 23793889
-
ICU-acquired weakness.Chest. 2007 May;131(5):1541-9. doi: 10.1378/chest.06-2065. Chest. 2007. PMID: 17494803 Review.
-
[Research progress in diagnosis and evaluation of intensive care unit-acquired weakness].Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021 Dec;33(12):1533-1536. doi: 10.3760/cma.j.cn121430-20210429-00647. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 35131027 Review. Chinese.
Cited by
-
Serum amyloid A1 mediates myotube atrophy via Toll-like receptors.J Cachexia Sarcopenia Muscle. 2020 Feb;11(1):103-119. doi: 10.1002/jcsm.12491. Epub 2019 Aug 23. J Cachexia Sarcopenia Muscle. 2020. PMID: 31441598 Free PMC article.
-
Dynamics of myosin degradation in intensive care unit-acquired weakness during severe critical illness.Intensive Care Med. 2014 Apr;40(4):528-38. doi: 10.1007/s00134-014-3224-9. Epub 2014 Feb 15. Intensive Care Med. 2014. PMID: 24531339 Clinical Trial.
-
Inflammation-induced acute phase response in skeletal muscle and critical illness myopathy.PLoS One. 2014 Mar 20;9(3):e92048. doi: 10.1371/journal.pone.0092048. eCollection 2014. PLoS One. 2014. PMID: 24651840 Free PMC article.
-
Deletion of Nlrp3 protects from inflammation-induced skeletal muscle atrophy.Intensive Care Med Exp. 2017 Dec;5(1):3. doi: 10.1186/s40635-016-0115-0. Epub 2017 Jan 17. Intensive Care Med Exp. 2017. PMID: 28097512 Free PMC article.
-
Functional Magnetic Neuromuscular Stimulation vs. Routine Physiotherapy in the Critically Ill for Prevention of ICU Acquired Muscle Loss: A Randomised Controlled Trial.Medicina (Kaunas). 2024 Oct 21;60(10):1724. doi: 10.3390/medicina60101724. Medicina (Kaunas). 2024. PMID: 39459511 Free PMC article. Clinical Trial.
References
-
- Fan E, Zanni JM, Dennison CR, Lepre SJ, Needham DM. Critical illness neuromyopathy and muscle weakness in patients in the intensive care unit. AACN Adv Crit Care. 2009;20:243–253. - PubMed
-
- Reid MB, Andrade FH, Balke CW, Esser KA. Redox mechanisms of muscle dysfunction in inflammatory disease. Phys Med Rehabil Clin N Am. 2005;16:925–949. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources